Clinical Trials Browser

HER2-positive Metastatic Breast Cancer × pertuzumab × 90 days × Clear all

NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Phase 2 Active not recruiting

19 enrolled 26 charts

HER2-positive Metastatic Breast Cancer